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ABSTRACT
Introduction: Troponin elevation is an
independent risk factor for mortality, but the
prognosis of patients with troponin elevation
and non-obstructive coronary artery disease
(CAD) is unknown. Recent data have
suggested an increased risk of mortality. This
study was performed to further investigate the
outcomes of troponin-positive patients with
obstructive and non-obstructive CAD.
Methods: A retrospective cohort analysis was
performed of all patients with raised troponin
presenting to Kettering General Hospital
(January 2010 to December 2011, n = 1,351).
The patients who had angiograms were
stratified anatomically into obstructive CAD
and non-obstructive CAD (B50% stenosis).
The obstructive CAD group (O-CAD) was sub-
analyzed by management strategy: emergency
re-vascularization (\12 h), urgent, delayed, and
medically managed. Patients with non-
obstructive CAD were grouped by the cause of
the raised troponin if this could be identified
(NO-CAD-I) or cause remained unidentified
(NO-CAD-U). The major adverse cardiac and
cerebrovascular event (MACCE) and mortality
rates were calculated at 30 days and 1-year
follow-up.
Results: There was a preponderance of
hypertension and severe renal impairment in
the non-obstructive CAD group. The patients
with NO-CAD-U were a low-risk group (MACCE
at 1-year follow-up = 0). The remaining NO-
CAD-I group had a similar risk to the O-CAD
group for MACCE and mortality at 30 days and
1-year follow-up. In fact, at 1-year follow-up,
the NO-CAD-I patients when compared with
the subgroups of O-CAD, had higher MACCE
rates and mortality compared with the
emergency re-vascularized group [MACCE:
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relative risk (RR) (95% CI) = 2.27 (1.29–3.40),
P = 0.0047; mortality: RR (95% CI) = 2.08
(1.10–3.93), P = 0.024]. This was driven by
higher risk non-cardiac death [RR (95%
CI) = 4.10 (1.53–10.99), P = 0.005].
Conclusion: Patients with identified cause for
raised troponin and non-obstructive CAD are at
equivalent risk of MACCE and mortality at
30 days and 1-year follow-up compared to
those with obstructive CAD.
Keywords: Coronary angiography; Coronary
artery disease; Major adverse cardiac and
cerebrovascular event; Mortality; Prognosis;
Troponin
INTRODUCTION
Several studies have been performed evaluating
the significance of a raised troponin in both
ischemic heart disease and non-cardiac
conditions [1]. While it has been found that
cardiac troponins are valuable in the diagnosis
of acute coronary syndromes (ACS), it has also
been shown to be elevated in other cardiac (e.g.,
heart failure, myositis) and non-cardiac
conditions (e.g., sepsis, renal failure,
pulmonary embolism) [2, 3].
The prognosis of patients with non-
obstructive coronary artery disease (CAD) is
unknown, but recent small studies have found
that patients with an elevated troponin level
and non-obstructive CAD have an increased risk
of death at 1-year follow-up, as well as death
and recurrence of myocardial infarction at
2.5 years follow-up [4–6], especially non-
cardiac causes of death [5]. This study was
performed to further investigate the outcomes
of troponin-positive patients with obstructive
and non-obstructive CAD.
METHODS
The analysis in this article does not involve any
new studies of human or animal subjects
performed by any of the authors. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008.
A retrospective cohort analysis that included
all patients who had a raised cardiac troponin T
(cTnT; AQT90 FLEX [Radiometer Medical ApS,
Brønshøj, Denmark], using the 99th percentile
value of 0.017 ng/ml) presenting to Kettering
General Hospital (Northamptonshire, UK)
between the period of January 2010 to
December 2011 was performed. These patients
were divided into two groups; the first group
comprised patients who underwent coronary
angiograms and the second group comprised
patients who were too high risk for coronary
angiograms and were medically managed. The
patients who had angiograms were stratified
anatomically, into non-obstructive epicardial
CAD with \50% stenosis (NO-CAD) and
obstructive epicardial CAD with C50% stenosis
(O-CAD). The NO-CAD patients were sub-
grouped by the cause of raised troponin if this
could be identified (NO-CAD-I) versus the group
where the cause remained unidentified (NO-
CAD-U). Also, the O-CAD cohort was analyzed
by management strategy: emergent
revascularization (\12 h); revascularization
performed urgently as inpatient (mean of
2 days); delayed revascularization as
outpatient; and medical management. The
30 days and 1-year major adverse cardiac and
cerebrovascular events (MACCE) and the
relative risk (RR) of death in the NO-CAD
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group were analyzed in comparison to O-CAD
group. Furthermore, analyses of the NO-CAD
subgroups were compared to the O-CAD
subgroups. The Modification of Diet in Renal
Disease equation (MDRD) equation was used to
calculate the glomerular filtration rate for all
patients [7].
Statistical Methods
The data were analyzed with the use of MedCalc
version 12.7.2 (MedCalc Software bvba, Ostend,
Belgium). The results were expressed as
percentage or mean ± standard deviation for
categorical and continuous variables,
respectively, due to normal population
distribution. Significant differences between
groups were assessed by v2 test and Student’s
t test in comparing between nominal and
continuous variables, respectively. One-way
analysis of variance test was used instead of
Student’s t test in cases of more than two
quantitative variables. Significance was
ascribed with probability \0.05. The Kaplan–
Meier survival curve was performed to compare
the rate of mortality at 30 days and 1-year
follow-up between the groups.
RESULTS
A total of 1,351 patients who presented to
Kettering General Hospital with raised cTnT
(from January 2010 to December 2011) were
assessed included in the study. Of these, 962
patients (71.2%) had coronary angiography,
and 389 patients (28.8%) were too high risk
for angiography and were therefore medically
managed. These patients had multiple
comorbidities, which included severe renal
impairment, peripheral vascular disease or
critical illness requiring mechanical
ventilation. Patients who had coronary
angiography were stratified anatomically into
those with O-CAD (847 patients, 62.6%) and
NO-CAD (115 patients, 8.5%; Fig. 1).
The NO-CAD-I comprised 80 patients
(69.5%) and the NO-CAD-U comprised 35
patients (30.4%). The O-CAD group comprised
374 patients who had emergency
revascularization (44.2%), 184 patients who
Fig. 1 Total number of patients. CAD, coronary artery disease
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had urgent revascularization as an inpatient
(21.7%), 114 patients who were discharged and
returned for delayed outpatient
revascularization (13.4%), and 175 patients
who were managed medically (20.6%).
The mean age was equivalent between both
groups and there were more female patients in
the NO-CAD group when compared with the
O-CAD. Comparing for risk factors for CAD
showed that the NO-CAD group had a
significant preponderance of hypertension (73
patients, 63% vs. 435 patients, 51%, P = 0.0068;
Table 1).
The NO-CAD group had a trend toward
lower level of cTnT elevation (0.5 ± 0.6 vs.
2.4 ± 4.7, P = 0.121) and a longer length of
hospital stay (9.1 ± 16.4 vs. 5.3 ± 7.9,
P = 0.253). The evaluation of the renal
functions showed that the NO-CAD group had
more patients with severe renal impairment
with a glomerular filtration rate \15 ml/min/
1.73 m2 (5 patients, 4.3% vs. 5 patients, 0.5%,
P = 0.0014; Table 2).
The comparison between the
echocardiographic findings showed no
structural heart disease by echocardiogram in
the NO-CAD group (43 patients, 37% vs. 178
patients, 21%, P\0.0001) and more patients
with aortic valve disease and left ventricular
hypertrophy (Table 3).
The 30 days MACCE and mortality rates were
similar between the NO-CAD and O-CAD
groups [30 days MACCE: RR (95% CI) = 0.72
(0.29–1.77), P = 0.47; 30 days all-cause
mortality: RR (95% CI) = 1.24 (0.54–2.86),
P = 0.6124]. At 1-year follow-up, the MACCE
rate between the NO-CAD and the O-CAD
groups was also equivalent [RR (95%
CI) = 1.21 (0.75–1.96), P = 0.43], with similar
1-year mortality in both groups [RR (95%
CI) = 0.93 (0.53–1.64), P = 0.803; Table 4].
The subgroup analysis of the NO-CAD group
showed that the 35 patients who had no
identifiable cause for the cTnT elevation were
a low-risk group (MACCE at 1-year = 0). In the
NO-CAD group, the most common identified
Table 1 Demographics and risk factors for CAD
Demographics and risk factors for CAD Non-obstructive CAD group Obstructive CAD group P value
N5 115 (8.5%) N5 847 (62.7%)
Age, years ± SD 67.3 ± 14.1 66.4 ± 13 0.981
Gender
Male 56 (48.7) 610 (72) 0.541
Female 59 (51.3) 237 (28)
Diabetes mellitus 18 (15) 175 (20) 0.220
Hypertension 73 (63) 435 (51) 0.006
Smoker 68 (59) 468 (55) 0.250
Ex-smoker 17 (14) 102 (12) 0.397
Dyslipidemia 8 (7) 77 (9) 0.454
Family history for CAD 3 (2) 25 (3) 0.837
Values are given as N (%) unless otherwise stated
CAD coronary artery disease, SD standard deviation
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causes were tachyarrhythmia (21%), respiratory
failure/severe pneumonia (6.9%), sepsis (6%),
and advanced malignancies (6%; Table 5).
When NO-CAD-I group was compared to the
O-CAD group, they had similar 30 days MACCE
and mortality rates [30 days MACCE: RR (95%






N5 115 (8.5%) N5 847
(62.7%)
Normal echocardiograma 43 (37.4) 178 (21) \0.0001
Severe/Moderate aortic valve disease 8 (6.9) 13 (1.5) 0.0005
Moderate to severe LVH 10 (8.7) 19 (2.2) 0.0003
Severe LV systolic impairment (EF\35%) 10 (8.7) 61 (7.2) 0.2615
Moderate LV systolic impairment (EF 44–35%) 11 (9.5) 116 (13.7) 0.2306
Mild LV systolic impairment (EF 45–55%) 11 (9.5) 144 (17) 0.0525
Regional wall motion abnormality 16 (13.9) 387 (45.7) \0.0001
Hypertrophic cardiomyopathy (Conﬁrmed by CMR) 1 (0.8) 0 (0.0) 0.0582
Takotsubo cardiomyopathy 1 (0.8) 0 (0.0) 0.0582
Moderate to severe valvular heart disease 2 (1.7) 35 (4.1) 0.2295
Others (Right ventricular function impairment, Pulmonary hypertension,
ASD, VSD or Previous valve replacement)
8 (6.9) 50 (5.9) 0.6551
No echocardiogram 16 (13.9) 137 (16.1) 0.5383
Values are given as N (%)
a Normal echocardiography with no structural heart disease
Table 2 Baseline anemia and renal impairment
Blood investigations Non-obstructive CAD group Obstructive CAD group P value
N5 115 (8.5%) N5 847 (62.7%)
Hemoglobin, g/dl (±SD) 12.7 ± 9.8 13.4 ± 3.4 0.639
Creatinine, lmol/l (±SD) 112.4 ± 94 94.9 ± 50 0.332
GFR (rate/min/1.73 m2) and grade of renal impairmenta
GFR[60 76 (66) 640 (75.5) 0.054
IIIa 45–59.9 18 (15.6) 107 (12.6) 0.360
IIIb 30–44.9 8 (6.9) 72 (8.5) 0.576
IV 15–29.9 8 (6.9) 24 (2.8) 0.023
V\15 5 (4.3) 5 (0.5) 0.0014
Values are given as N (%) unless otherwise stated
a Grades of renal impairment by MDRD equation
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CI) = 1.03 (0.42–2.52), P = 0.934; 30 days all-
cause mortality: RR (95% CI) = 1.68 (0.71–3.73),
P = 0.25]. The 1-year MACCE and mortality
follow-up rates were also similar [1-year
MACCE: RR (95% CI) = 1.21 (0.75–1.96),
P = 0.43; 1-year all-cause mortality: RR (95%
CI) = 1.34 (0.77–2.33), P = 0.31].
Further comparison of NO-CAD-I patients
with the O-CAD subgroups showed no
difference in 30 days MACCE and mortality
rates. However, at 1-year follow-up, NO-CAD-I
patients had higher MACCE rates and overall
mortality compared to the emergency re-
vascularization group [1-year MACCE: RR (95%
CI) = 2.27 (1.29–3.40), P = 0.0047; 1-year all-
cause mortality: RR (95% CI) = 2.08 (1.10–3.93),
P = 0.024]. This increased mortality was driven
by non-cardiac death [RR (95% CI) = 4.10
(1.53–10.99), P = 0.005; Fig. 2).
DISCUSSION
Previous studies indicated that the detection of
the highly specific troponin in blood is an
independent risk factor that identifies patients
presenting with unstable angina or non-ST





Relative risk (95% CI) P value
N5 115 (8.5%) N5 847 (62.7%)
30 days follow-up
MACCE 5 (4.3) 51 (10.4) 0.7221 (0.29–1.77) 0.4771
Death
Total 6 (5.2) 39 (4.6) 1.24 (0.54–2.86) 0.6124
Cardiac 4 (3.4) 30 (3.5) 0.98 (0.35–2.74) 0.9723
Non-cardiac 2 (1.7) 9 (1.0) 1.63 (0.36–7.48) 0.5252
1-year outcome
MACCE 15 (13.0) 131 (15.4) 0.84 (0.51–1.39) 0.5021
Total 12 (10.4) 95 (11.2) 0.93 (0.53–1.64) 0.8032
Cardiac 5 (4.3) 48 (5.6) 0.77 (0.31–1.89) 0.5640
Non-cardiac 7 (6.0) 43 (5.0) 1.2 (0.55–2.60) 0.6461
MI
STEMI 2 (1.7) 24 (2.8) 0.61 (0.12–2.56) 0.5033
NSTE-ACS 0 (0.0) 25 (2.9) 0.14 (0.01–2.34) 0.1727
Unplanned revascularization 2 (1.7) 49 (5.8) 0.3 (0.07–1.22) 0.0925
CVA/TIA 1 (0.8) 7 (0.8) 1.05 (0.13–8.47) 0.9619
Major bleedinga 3 (2.6) 24 (2.8) 0.92 (0.28–3.01) 0.8912
CAD coronary artery disease, CVA cerebrovascular stroke, MACCE major adverse cardiac and cerebrovascular events, MI
myocardial infarction, NSTE-ACS non-ST elevation ACS, STEMI ST elevation myocardial infarction, TIA transient
ischemic attack
a Major bleeding that required blood transfusion
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elevation myocardial infarction, who are at
increased risk of death [8, 9]. Troponin
elevation can be seen in a variety of clinical
scenarios, which may lead to its detection in the
absence of thrombotic ACSs. Many disease
states, such as sepsis, hypovolemia, atrial
fibrillation, congestive heart failure,
pulmonary embolism, myocarditis, myocardial
contusion, renal failure, and critically ill
patients can be associated with a raised
troponin level (Table 6) [9–13].
In several studies of ACSs, troponin elevation
has been associated with a worse prognosis [9,
14]. However, troponin elevation in the absence
of thrombotic ACS still retains the prognostic
value [9]. The risk for subsequent death appears
to be related to the degree of troponin elevation
[8]. There is a significant increase in mortality
with increasing levels of troponin, and the RR
for death is 7.8 in patients with the high
troponin levels compared to those with
normal levels [8]. The short- and long-term
survival rates are impaired among patients with
troponin elevation in many different clinical
settings, including congestive heart failure,
sepsis, pulmonary disease, acute pulmonary
embolism, and renal insufficiency [15]. The
reasons for this increase in mortality are
currently poorly understood, but may be
related to myocardial necrosis with myocyte
loss or underlying quiescent CAD [9].
These findings challenge the idea that these
are ‘‘false-positive’’ troponin elevations and that
these patients may be regarded as low risk for
subsequent cardiovascular events [16].
Elevation of troponin in these patients may
result from coronary atherothrombosis not
evident using standard angiography or from
other ischemic and non-ischemic mechanisms
[16]. It was also previously shown that the
incidental troponin rise was more common in
older patients and was associated with a poorer
prognosis compared to ACSs [17]. Given this
substantially increased risk for adverse
Fig. 2 Kaplan–Meier survival curve. I/P PCI inpatient
percutaneous coronary intervention, Medical Mx medical
therapy, O/P PCI outpatient percutaneous coronary
intervention, PCI percutaneous coronary intervention
Table 5 Causes of raised troponin in non-obstructive
CAD group
Identiﬁed cause N5 115 %
Tachyarrhythmia 25 21.7
Respiratory failure/Severe pneumonia 8 6.9
Sepsis 7 6.0
Advanced malignancy 7 6.0
Heart failure 6 5.2
Myopericarditis 5 4.34
Takotsubo syndrome 4 3.47
Aortic valve disease 4 3.47
Suspected vasospastic angina 2 1.7
Pulmonary embolism 2 1.7
Bradyarrhythmia 2 1.7
Critically ill with ITU admission 2 1.7
Cerebrovascular Stroke 0 0.0
Acute kidney injury 10 0.86
Aortic dissection 1 0.86
Unknown 35 30.4
IHD 0 0.0
Post-PCI troponin rise 0 0.0
CAD coronary artery disease, ITU intensive care unit, PCI
percutaneous coronary intervention
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outcomes, patients with troponin elevation in
general require appropriate diagnostic
evaluation and therapy aimed at the
underlying disorder [9].
A previous study by Mehta et al. [4]
compared patients who had elevated troponin
levels and\50% stenosis of any major coronary
artery on angiography (n = 83) to patients with
negative troponin levels. The patients with
elevated troponin and non-obstructive-
epicardial CAD had an increased incidence of
death and recurrence of myocardial infarction
at 2.5 years follow-up [4].
The current study compared patients with
elevated cTnT with non-obstructive CAD versus
obstructive epicardial CAD. The MACCE rate
was similar at 30 days and 1-year follow-up. The
mortality rate at 30 days follow-up for the non-
obstructive CAD was 5.2% vs. 4.6% in the high-
risk obstructive CAD group with a RR (95% CI)
of 1.24 (0.54–2.86) (P = 0.61). The rate of
mortality at 1-year follow-up was 10.4% vs.
11.2% with a RR (95% CI) of 0.93 (0.53–1.64)
(P = 0.8). This was similar to the results of the
previous sub-study of the ACUITY trial, which
showed that the patients with non-ST elevation
ACS and elevated troponin but without
obstructive CAD are still at considerable risk
for 1-year mortality from cardiac and non-
cardiac causes [5]. This may be caused by
unstable, ruptured plaques, but with no
significant coronary lesions by angiography.
A small study by Ohlmann et al. [18]
evaluated patients who had intravascular
Table 6 Causes of raised troponin
• Chronic or acute renal dysfunction
• Severe congestive heart failure—acute and chronic
• Hypertensive crisis
• Tachy- or brady-arrhythmias
• Pulmonary embolism, severe pulmonary hypertension
• Inﬂammatory diseases, e.g., myocarditis
• Acute neurological disease, including stroke or subarachnoid hemorrhage
• Aortic dissection, aortic valve disease or hypertrophic cardiomyopathy
• Cardiac contusion, ablation, pacing, cardioversion, or endomyocardial biopsy
• Hypothyroidism
• Apical ballooning syndrome (Takotsubo cardiomyopathy)
• Inﬁltrative diseases, e.g., amyloidosis, hemochromatosis, sarcoidosis, scleroderma
• Drug toxicity, e.g., adriamycin, 5-ﬂuorouracil, Herceptin, snake venoms
• Burns, if affecting[30% of body surface area
• Rhabdomyolysis
• Critically ill patients, especially with respiratory failure, or sepsis
Information from: European Society of Cardiology (ESC) Guidelines for the management of ACS in patients presenting
without persistent ST-segment elevation. The Task Force for the management of ACS in patients presenting without
persistent ST-segment elevation of the ESC, 2011 [16]
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ultrasound showing ruptured plaques with no
significant angiographic disease. They had a
high death rate of 6% and a major adverse
cardiac events (MACE) rate of 18% at a mean
follow-up of 43 months [18].
This was also similar to the TACTICS-TIMI-
18 sub-study, which followed a total of 895
patients, from which 32 patients had positive
troponin and non-obstructive CAD and they
were compared to the three other groups for
6-month mortality, re-infarction, or re-
admission for ACS at 6-month follow-up. This
sub-study demonstrated that those patients had
an adverse prognosis with no significant
difference in outcome between troponin-
positive patients with CAD compared with
those without CAD (P = 0.20) [16, 19].
However, this was in contrary to the previous
study by Segev et al. [17] which showed that the
patients with non-obstructive CAD had a
benign clinical outcome compared with those
with normal coronary arteries during an
intermediate term follow-up of 2.5 years with
equal low MACE rate between the two groups.
(1% for both groups; P = 0.9) [17].
Subgroup analysis has not previously been
carried out. By sub-grouping the non-
obstructive CAD group, we have shown that
patients in the non-obstructive CAD group
with no identified cause for the raised
troponin were at low risk at 1-year follow-up
(MACCE at 1-year = 0). In the non-obstructive
CAD group with identified cause, the most
common causes of raised troponin were
tachyarrhythmia, respiratory failure/severe
pneumonia, sepsis and advanced malignancies
(Table 6). This has been demonstrated in
previous studies, with elevation Troponin in
many different clinical settings, including
congestive heart failure, sepsis, pulmonary
disease, acute pulmonary embolism, and renal
insufficiency [20–22]. The mechanism of
troponin release is unknown in the absence of
flow-limiting CAD, suggesting the presence of
mechanisms other than thrombotic coronary
artery occlusion, probably a transient loss in
membrane integrity with subsequent troponin
leakage or micro-vascular thrombotic injury
[23].
Further comparison of this non-obstructive
CAD group with identified cause to the
obstructive CAD management subgroups
demonstrated that these patients had higher
1-year MACCE rate and overall mortality
compared with the emergency revascularized
group. This increased mortality was driven by
higher risk of non-cardiac death [RR (95%
CI) = 4.10 (1.53–10.99), P = 0.005; Fig. 2).
CONCLUSION
Patients with a raised troponin and non-
obstructive CAD with an identified cause are
at equivalent risk of MACCE and death at
30 days and 1-year follow-up compared to
those with obstructive CAD. Patients in the
non-obstructive CAD group were at a similar
risk whether managed with urgent or delayed
revascularization or medical therapy for
obstructive CAD, with the best outcomes seen
in the emergency revascularization group. This
finding challenges the prevailing perception
that these patients form a low-risk group.
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